Text Size

Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer (ICEBERG 3)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00628251
First received: February 26, 2008
Last updated: February 13, 2013
Last verified: February 2013
History of Changes
  Purpose

The purpose of the study is to compare the efficacy and safety of 2 doses of drug AZD2281 against liposomal doxorubicin to see which is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced ovarian cancer and who have failed previous platinum therapy.


Condition Intervention Phase
Ovarian Neoplasms
 Drug: AZD2281
Drug: Liposomal Doxorubicin
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II, Open-Label, Randomised, Comparative, International Multicentre Study to Assess the Safety and Efficacy of Different Doses of AZD2281 Given Orally Twice Daily Versus Intravenous Liposomal Doxorubicin Given Monthly in Patients With Advanced BRCA1- or BRCA2-Associated Ovarian Cancer Who Have Failed Previous Platinum-based Chemotherapy

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Efficacy comparison of 400 mg bd and 200 mg bd AZD2281 v 50mg/m2 doxil every 4 weeks in BRCA1 or 2 associated advanced ovarian cancer patients by PFS (primary variable), ORR, duration of response and CA-125 levels [ Time Frame: every 4 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Comparison of safety and tolerability [ Time Frame: every 4 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 97
Study Start Date: July 2008
Estimated Study Completion Date: December 2013
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
AZD2281 Oral
 Drug: AZD2281
400mg Oral twice daily
Other Name: Olaparib
Drug: AZD2281
200mg oral twice daily
Active Comparator: 2
Liposomal Doxorubicin
 Drug: Liposomal Doxorubicin
50mg/m2 Monthly Intravenous
Other Name: Doxil®

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Advanced ovarian cancer with positive BRCA1 or BRCA2 status
  • Progressive or recurrent disease after platinum-based chemotherapy
  • Measurable disease by RECIST

Exclusion Criteria:

  • Previous anthracycline treatment
  • Brain metastases
  • Less than 28 days since last treatment used to treat the disease
  • Considered a poor medical risk due to a serious uncontrolled disorder
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00628251

  Hide Study Locations
Locations
United States, California
Research Site
Duarte, California, United States
Research Site
Los Angeles, California, United States
Research Site
San Francisco, California, United States
United States, Florida
Research Site
Boca Raton, Florida, United States
United States, Massachusetts
Research Site
Boston, Massachusetts, United States
United States, New York
Research Site
New York, New York, United States
United States, Texas
Research Site
Houston, Texas, United States
Australia, New South Wales
Research Site
Randwick, New South Wales, Australia
Australia, Victoria
Research Site
Melbourne, Parkville, Victoria, Australia
Australia
Research Site
VIC, Australia
Belgium
Research Site
Brussels (jette), Belgium
Research Site
Leuven, Belgium
Germany
Research Site
Koln, Germany
Research Site
Munchen, Germany
Israel
Research Site
Haifa, Israel
Research Site
Petah Tikva, Israel
Research Site
Tel Aviv, Israel
Research Site
Tel-hashomer, Israel
Poland
Research Site
Szczecin, Poland
Spain
Research Site
Barcelona, Cataluna, Spain
Research Site
Hospitalet Dellobregat(barcelo), Cataluna, Spain
Sweden
Research Site
Lund, Sweden
United Kingdom
Research Site
Sutton, Surrey, United Kingdom
Research Site
Cambridge, United Kingdom
Research Site
Edinburgh, United Kingdom
Research Site
London, United Kingdom
Research Site
Manchester, United Kingdom
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Jane Robertson, BSc, MBCHB, MD AstraZeneca
Principal Investigator: Stan Kaye, BSc, MB, FRCP, FRCR, SMedSCi Royal Marsden NHS Foundation Trust
  More Information

No publications provided by AstraZeneca

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00628251     History of Changes
Other Study ID Numbers: D0810C00012
Study First Received: February 26, 2008
Last Updated: February 13, 2013
Health Authority: United States: Food and Drug Administration
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Australia: Department of Health and Ageing Therapeutic Goods Administration
Germany: Federal Institute for Drugs and Medical Devices
Sweden: Medical Products Agency
Spain: Ministry of Health
Israel: Ministry of Health
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Belgium: Federal Agency for Medicinal Products and Health Products

Keywords provided by AstraZeneca:
Advanced ovarian cancer
BRCA1 protein
BRCA2 protein
Poly(ADP ribose) polymerases

Additional relevant MeSH terms:
Neoplasms
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
 Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Doxorubicin
Antibiotics, Antineoplastic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 23, 2013